Global Health Governance
Global health governance refers to the collective rules, institutions, and processes that coordinate responses to health threats that cross national borders. In an IR context, it raises core questions about sovereignty, cooperation, and inequality: Who decides when a disease is a global emergency? How do you get 190+ countries to share information and resources when their interests diverge?
World Health Organization and International Regulations
The World Health Organization (WHO) is the primary international body for global health coordination. Established in 1948 as a UN specialized agency, it sets health standards, provides technical assistance to countries, and leads responses to health emergencies.
The WHO's main legal tool is the International Health Regulations (IHR), last revised in 2005 after the SARS outbreak. The IHR create a binding framework that requires member states to:
- Report certain disease outbreaks and unusual public health events to the WHO
- Develop minimum core capacities for disease surveillance and response
- Allow WHO to declare a Public Health Emergency of International Concern (PHEIC), which triggers coordinated global action
Global health security is the broader goal behind these regulations: preventing, detecting, and responding to infectious disease threats before they spiral into crises. Various initiatives (like the Global Health Security Agenda, launched in 2014) aim to strengthen national and international capacities, especially in countries with weaker health infrastructure.
A recurring tension here is sovereignty vs. transparency. States sometimes delay reporting outbreaks because of fears about economic damage from trade restrictions or travel bans. The IHR tries to address this by discouraging unnecessary trade/travel measures, but compliance remains uneven.
One Health Approach and Collaborative Efforts
The One Health approach recognizes that human health, animal health, and environmental conditions are deeply interconnected. About 75% of emerging infectious diseases in humans are zoonotic, meaning they originate in animals. That makes this more than an abstract idea.
One Health promotes collaboration across sectors that don't traditionally work together:
- Medical professionals and veterinarians sharing disease surveillance data
- Ecologists tracking how habitat destruction increases human-animal contact
- Policymakers designing regulations that address food safety, land use, and drug use in livestock simultaneously
One Health strategies target problems like zoonotic diseases (Ebola, avian flu, COVID-19's likely origins), food safety, and antimicrobial resistance in agricultural settings. Key international partners include the WHO, the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (WOAH).
The challenge is implementation. One Health requires countries to build cross-sector surveillance systems and fund research programs that span disciplines, which is difficult even in wealthy nations.
Pandemics and Responses
Pandemic Characteristics and Global Impact
A pandemic is a widespread infectious disease outbreak that crosses multiple countries or continents. It differs from an epidemic, which is more geographically contained.
Major historical pandemics include the 1918 influenza pandemic (estimated 50 million deaths), cholera pandemics of the 19th century, and the ongoing HIV/AIDS crisis (approximately 40 million deaths since the 1980s). The COVID-19 pandemic became the defining case study for this generation, exposing vulnerabilities in even the most advanced health systems.
Pandemic responses generally require coordination across several areas:
- Surveillance: Detecting and tracking the spread of disease
- Containment: Quarantines, border controls, and contact tracing to slow transmission
- Mitigation: Treatments, vaccines, and public health measures to reduce harm once containment fails
The impacts extend well beyond health. Economically, pandemics disrupt global trade, travel, and supply chains. Socially, they cause education disruptions, behavioral changes, and significant mental health consequences. COVID-19 alone caused an estimated $12.5 trillion in global economic losses through 2024, according to IMF estimates.
Vaccine Diplomacy and Health Inequities
Vaccine diplomacy is the use of vaccine development and distribution as a foreign policy tool. Countries like China, Russia, and India distributed vaccines internationally during COVID-19 partly to build soft power and strengthen diplomatic relationships, especially with developing nations.
The COVAX initiative, co-led by the WHO, Gavi (the Vaccine Alliance), and CEPI, was created to ensure equitable global access to COVID-19 vaccines. Its goal was to prevent a scenario where wealthy countries hoarded supply while poorer nations went without. Results were mixed: COVAX delivered over 1.9 billion doses, but high-income countries secured far more vaccines per capita and much earlier.
This points to deeper health inequities in the international system:
- Low-income countries often lack manufacturing capacity, cold-chain storage, and trained health workers to distribute vaccines
- Disparities in healthcare infrastructure mean diseases that are treatable in wealthy nations remain deadly elsewhere
- Intellectual property rules (like patents on vaccines) became a major debate, with developing countries pushing for temporary patent waivers
Addressing these gaps requires resource sharing, technology transfer, and sustained investment in health systems, not just emergency responses during crises.
Antimicrobial Resistance and Global Health Challenges
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, or parasites evolve to survive drugs designed to kill them. The WHO considers AMR one of the top ten global public health threats. A 2022 Lancet study estimated that bacterial AMR was associated with roughly 4.95 million deaths globally in 2019.
AMR develops primarily through:
- Overuse of antibiotics in human medicine (prescribing them for viral infections where they have no effect)
- Misuse in agriculture, where antibiotics are used to promote livestock growth or prevent disease in crowded conditions
- Patients not completing full courses of antibiotics, allowing partially resistant bacteria to survive
The WHO Global Action Plan on Antimicrobial Resistance (2015) provides a framework built around five objectives: improving awareness, strengthening surveillance, reducing infections, optimizing antimicrobial use, and increasing investment in new drugs and diagnostics.
The core problem is that developing new antibiotics is expensive and not very profitable for pharmaceutical companies, since antibiotics are used for short courses (unlike drugs for chronic conditions). This creates a market failure that requires public investment and innovative funding models to solve.
AMR connects directly to the One Health framework, since resistant bacteria move between humans, animals, and the environment. Tackling it demands the kind of cross-border, cross-sector cooperation that makes global health governance both necessary and difficult.